Clinical Pharmacology of Plozasiran

IF 3.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

American Journal of Cardiovascular Drugs Pub Date : 2026-06-24 DOI:10.1007/s40256-026-00808-6

Jessica Huston, Dontia Orey, Kelli Corona, Andrew Ashchi, Andrea Ashchi Lachapelle, Elias Deeb, Alexander Deeb, Rambod Rouhbakhsh, Jason Berner, David Sutton, Wasim Deeb, Majdi Ashchi, Amir Azarbal, Rebecca F. Goldfaden

引用次数: 0

Abstract

Hypertriglyceridemia can increase the risk of acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD). Patients with familial chylomicronemia syndrome are at an even higher risk of developing pancreatitis due to elevated triglycerides. A pathway involving small interfering RNA that selectively inhibits apolipoprotein C-III (APOC3) messenger RNA through RNA interference is currently being studied to reduce levels of apoC-III and thus, triglycerides. This review presents and discusses the current pharmacokinetic, pharmacodynamics, and clinical and scientific evidence pertaining to plozasiran, a small interfering RNA medicine.

查看原文本刊更多论文

plzasiran的临床药理学。

高甘油三酯血症可增加急性胰腺炎和动脉粥样硬化性心血管疾病（ASCVD）的风险。由于甘油三酯升高，家族性乳糜微粒血症综合征患者发生胰腺炎的风险更高。目前正在研究一种涉及小干扰RNA的途径，通过RNA干扰选择性地抑制载脂蛋白C-III （APOC3）信使RNA，从而降低apoC-III的水平，从而降低甘油三酯的水平。这篇综述介绍并讨论了目前的药代动力学、药效学、临床和科学证据有关的plzasiran，一种小干扰RNA药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Cardiovascular Drugs 医学-心血管系统

CiteScore

6.70

自引率

3.30%

发文量

审稿时长

>12 weeks

期刊介绍： Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents. Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations. The American Journal of Cardiovascular Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.